ESCRS - Congenital corneal opacification ;
ESCRS - Congenital corneal opacification ;

Congenital corneal opacification

There is a groundswell of desire to re-examine the current nomenclature for congenital or neonatal corneal opacities

Congenital corneal  opacification
TBC Soosan Jacob
Published: Sunday, December 3, 2017
Ken Nischal MD addressing delegates at the 4th World Congress of Paediatric Ophthalmology and Strabismus in Hyderabad, India There is a groundswell of desire to re-examine the current nomenclature for congenital or neonatal corneal opacities, according to key opinion leaders attending the 4th World Congress of Paediatric Ophthalmology and Strabismus in Hyderabad, India. Aimed at reaching a consensus towards this, a session titled “Congenital Corneal Opacification Nomenclature, Time for a Change” was chaired by Ken Nischal MD. Following an audience vote, it was determined that it was time for a change in the nomenclature. Of all the terms discussed, there appeared to be consensus that “sclerocornea” was a misleading term both clinically and histologically. The cornea in “sclerocornea’ is not scleral tissue but abnormal corneal tissue. Through WSPOS and other key societies, all interested individuals and societies were encouraged to express an interest in forming a working group. Led by Drs. Serafino, Nucci and Nischal, a Delphi consensus process was planned to attain common ground and reach a consensus for a new nomenclature system for congenital or neonatal corneal opacities. The Delphi system relies on a structured communication system between a panel of experts who answer questionnaires in rounds, after each of which a summary is provided and experts can revise their previous stand in light of replies by other participant experts. In this case, electronic questionnaires are planned followed eventually by a face to face meeting of as many participants of the electronic questionnaire as possible.
Tags: paediatric
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Read more...

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

Read more...

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Read more...

Best of ESCRS Winter Meeting 2024

Read more...

Following the New Generation

EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.

Read more...

Refocus on Multifocals

Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.

Read more...

Common Myths in Presbyopia Correction

Patient education key to satisfaction with refractive IOLs.

Read more...

Reversible Multifocality

Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.

Read more...

Managing a Cataract Surgery Refractive Miss

Weighing the pros and cons of options for intraocular intervention.

Read more...

Unleashing OCT’s Full Potential

Performance of newest tool for corneal evaluation meets or beats older standard technologies.

Read more...

;